CAGE Bio

Focus: CAGE Bio is a pre-revenue biotech focused on deep eutectic ionic liquids (DEILs) as a platform technology for topical therapeutics, based in San Carlos, CA. Founded in 2020, the company is in early-stage development with a diversified dermatology pipeline.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About CAGE Bio

AI assessmentNot Hiring

No open roles listed right now. Follow CAGE Bio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

10 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CB-0002B

Erythema

N/A

Clinical Trials (1)

NCT0449867650 Human Subject Repeat Insult Patch Test

N/A

Help build intelligence for CAGE Bio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Proprietary platform technology (DEILs) with potential to differentiate topical formulations across multiple dermatology indications
Portfolio breadth across rosacea, atopic dermatitis, vitiligo, fungal infections, and bacterial overgrowth provides exposure to varied therapeutic areas
Ground-floor opportunity at 4-year-old biotech with active clinical programs and early-stage pipeline momentum

Watch Out For

No revenue, no disclosed funding, and financial stability is unclear—typical pre-revenue biotech cash runway risk
Only 1 advertised open role and undisclosed employee count suggests minimal near-term hiring or possible resource constraints
No Phase 3 programs and no recent publications publicly visible raise questions about clinical validation and scientific visibility

Generated by Claude from CAGE Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

CGB-400 Topical Gel

Fungal Infection

N/A

Clinical Trials (1)

NCT05202366An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection

N/A

CGB-400

Rosacea

PHASE_1

Clinical Trials (1)

NCT04508660CGB-400 for the Reduction of Facial Redness

Phase 1